Monday, 21 June 2021

Peer-Reviewed Scientific Paper Confirms Safety of Water Treated by BioLargo’s Advanced Oxidation System

Study demonstrates AOS generates less disinfection by-products than common wastewater treatment technologies 

Westminster, CA – June 21, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced the publication of a peer-reviewed scientific paper about its patented energy-efficient water disinfection technology the Advanced Oxidation System (AOS). The paper, which focused on quantifying the disinfection by-products generated by the AOS, represents a critical milestone in the commercialization of BioLargo’s innovative water treatment technology.

BioLargo’s ground-breaking AOS technology is a water treatment platform that provides high-level disinfection and consumes less electricity than competing technologies such as UV and ozone-based systems.  Significantly, the AOS removes pharmaceutical micropollutants from water to provide added value across diverse water treatment applications, including municipal wastewater treatment.

The study, led by the laboratory of Dr. Susana Kimura-Hara at the University of Calgary, assessed the disinfection by-products (DBPs) generated by the BioLargo AOS. The paper concluded that the levels of DBPs generated by the AOS were comparable to those found in ordinary tap water.

The paper’s abstract and summary can be accessed here: https://www.sciencedirect.com/science/article/abs/pii/S0043135421005388

As all water treatment technologies generate DBPs, the quantity and relative safety of disinfection byproducts generated by a given water treatment technology is an important consideration for customers deciding which technology to select for their needs. The results of this study therefore represent an important milestone for the AOS, which has a municipal wastewater treatment demonstration pilot underway near Montréal, Québec and is currently being readied for commercial trials.

This study corroborates the results of another peer-reviewed paper published earlier this year that showed the AOS does not increase the toxicity of treated water. Notably, that study also showed the AOS to be capable of negating the negative effects of two hard-to-treat micropollutants, with the paper’s author Dr. Greg Goss calling the AOS, “a major technical breakthrough for the treatment of micropollutants.


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Monday, 7 June 2021

BioLargo 2021 Annual Meeting of Stockholders Tuesday, June 15, 2021, 10:00 AM Pacific Time

Westminster, CA – June 7, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable clean- technologies and full-service environmental engineering company, will host its annual stockholder meeting on Tuesday June 15, 2021, at 10:00 am Pacific Time, via live webcast. In light of the continuing public health impact of the ongoing COVID-19 pandemic and to support the health and safety of the Company’s stockholders and attendees, the 2021 Annual Meeting will be held in a virtual-only meeting format.

Stockholders may register to attend the online Annual Meeting at this link:

https://agm.issuerdirect.com/blgo

Members of the Board and Management team will discuss the Company’s most recent annual and quarterly results and other general company matters, followed by a question-and-answer session with stockholders and management.

It is important that your shares be represented and voted at the Annual Meeting, whether or not you     plan to attend online. Stockholders of record as of April 19, 2021, may vote at the Annual Meeting. Please review the proxy statement and vote in accordance with the instructions you received.  

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Friday, 4 June 2021

BioLargo (BLGO) to Present at LD Micro Invitational XI

Presentation on Wednesday, June 9 at 5:00 PM ET

Westminster, CA – June 4, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it will be giving an investor presentation at the upcoming LD Micro virtual event on Wednesday, June 9, 2021, at 5:00 PM ET. BioLargo President and CEO Dennis P. Calvert will be giving the presentation.

Mr. Calvert will be discussing the company’s soon-to-launch sustainable water treatment technologies including its innovative solution for treating water contaminated with per- and polyfluoroalkyl substances (PFAS). Used in fire retardants and industrial facilities, PFAS contaminate municipal drinking water supplies across the country and the world, and represent a serious threat to human health.

“We got ahead of the curve by developing and commercializing an affordable and environmentally conscious technology that removes these toxic chemicals,” said Mr. Calvert. “The BioLargo AEC represents the most practical solution for this serious global problem. Watch our presentation to learn more about it and about our other emerging cleantech solutions.”

Event: BioLargo Presentation at the LD Micro Invitational XI

Date: Wednesday, June 9, 2021

Time: 5:00 PM Eastern

Register to watch the presentation at https://ldmicrojune2021.mysequire.com

Summary of LD Micro Invitational XI Event

The 2021 LD Micro Invitational will be held on the Sequire Virtual Events platform on Tuesday, June 8th - Thursday, June 10th, 2021.

This three-day, virtual investor conference is expected to feature around 180 companies, presenting for 25 minutes each, as well as several influential keynotes. The first day of this conference will also feature an exceptional one-time event: the LD Micro Hall of Fame.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

About LD Micro (NASDAQ: SRAX)

LD Micro aims to be the most crucial resource in the micro-cap world. Whether it is the index, comprehensive data, or hosting the most significant events on an annual basis, LD's sole mission is for the Texas Rangers to win the World Series and serve as an invaluable asset for all those interested in finding the next generation of great companies.

http://www.ldmicro.com

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Thursday, 27 May 2021

BioLargo (BLGO) Discusses Elimination of Convertible Debt and Progress on Commercialization of PFAS Treatment Technology with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - May 27, 2021) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a company that invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. President and CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Everett Jolly for an interview.

Jolly began the interview by commenting on the company's latest announcements, including a recent press release detailing the elimination of almost all of the company's convertible debt. "We took quite a bit of risk [three years ago]; we needed that capital and we have put it to great work. We have advanced two platform technologies that are now at a commercial-ready stage, they're dramatic and they have a big future," said Calvert. "The opportunities that are coming to us are so big and so expansive, and it's really a tribute to our great technology and to our people."

"We really needed to get that convertible debt out of the way," continued Calvert, noting that the company's debt peaked at $7.6 million in 2018. "Since then, we have retired all [but $50,000] of this convertible debt, which has been continuing to put pressure on the stock. So, it's a great moment."

Jolly then commented on the company's recent revenues and growth. "I think we're just scratching the surface," said Calvert. "We have put a couple of really key relationships together. We have new technologies coming into our portfolio. We are incredibly active and dynamic in developing commercial and revenue opportunities of significance."

"Could you give us an update on the company's PFAS project?" asked Jolly. "It's a very exciting opportunity," said Calvert. "There is a mandate by the Biden Administration to get this cleaned up. The beauty of this situation is that we got a little bit of a head start before it crescendoed in the market, which means we have the talent and the technical solution advanced sufficiently to be in commercial mode now."

"We would like to be in the field within the next 60-120 days. [PFAS] is a contaminant that has to come out; it is the environmental disaster of the decade," he explained. "We just think this is such an enormous opportunity. We're going to take it from start to finish and prove that it is a commercially viable, economic, and environmentally-friendly solution. Then we're going to partner with companies and take it all over the world."

Calvert then elaborated on the potential customers for this industry, which will likely include the military, municipal, and industrial clients. "Who serves those people? There are really two classes: environmental engineering firms and specialty large companies dedicated to water," explained Calvert. "Both of those are really distributor and partner opportunities for us."

"What is the outlook for your company over the next twelve months?" asked Jolly. "The hardest work is done," said Calvert. "We have never been more excited than today... we have some financing that really provides the resources to get us through this commercial gap," he continued. "I think this is a time where investor enthusiasm is at an all-time high and it will continue. So, we're a company to watch."

"You need to watch carefully, because the evolution of this company is so dynamic that if you're not looking every six months you will only know about half the story," said Calvert. "The hard work is done, the prize is in front of us, let's go do the work and get it done."

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7875307-biolargo-blgo-discusses-elimination-of-convertible-debt-and-progress-on-commercialization-of-pf

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/


About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:

Stock Day Media

(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/85514

Monday, 24 May 2021

BioLargo Strengthens its Balance Sheet by Eliminating Convertible Debt to Position Company for Growth

Westminster, CA – May 24, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it has eliminated nearly all of its convertible debt. The announcement comes as a result of the company having paid off $406,000 in convertible debt that would have come due in August of 2021, through the payment of cash and equity, as reported on Form 8-K filed May 19, 2021. Other than debt owed by its partially owned subsidiary Clyra Medical Technologies, Inc., only Small Business Association and Paycheck Protection Program (PPP) loans totaling $464,000 ($314,000 of which has been applied for forgiveness), and $50,000 of fixed-price convertible debt (due in 2023) remain on BioLargo’s balance sheet.

Dennis P. Calvert, President & CEO of BioLargo discussed the news: “This is quite an accomplishment considering just three years ago we had $7.6 million of debt on our balance sheet. With our financing commitment having over $6 million remaining, we are confident that we can continue to fund our operational needs as we launch our exciting new environmental technologies and grow our revenue.

BioLargo took significant risk three years ago by investing heavily in its environmental platform technologies and the infrastructure to support them, especially its patented low-energy advanced water treatment technology the Advanced Oxidation System (AOS), and the Aqueous Electrostatic Concentrator (AEC), an affordable and eco-friendly solution to treat water contaminated with per- and poly-fluoroalkyl substances (PFAS) (learn more about the worldwide PFAS problem at our blog: https://biolargo.blogspot.com/2021/02/biolargo-answers-administrations-urgent.html). Since that time, the company has advanced both technologies to a point of commercial readiness, with the AOS have already been successfully deployed in several demonstration pilot projects.

BioLargo also made the bold move to form its own engineering company, BioLargo Engineering, Science & Technologies, LLC, located in Oak Ridge, Tennessee. Mr. Calvert commented, “Our engineering division has become a pillar of our company, having played a crucial role in the development and scaling up our AOS and AEC technologies. Our company-wide revenues also have grown significantly, helping make it possible to pay off the debt we used to finance these ambitious development efforts.”

Mr. Calvert ended with, “With this debt behind us, our platform technologies ready for commercial launch, and key industry partnerships taking shape, it’s time to grow our business.”


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Thursday, 20 May 2021

BioLargo AEC Technology Highlighted as Emerging PFAS Water Treatment Solution in Global Water Intelligence Article

BioLargo’s patented water treatment technology designed for per- and poly-fluoroalkyl substances (PFAS), called the BioLargo Aqueous Electrostatic Concentrator (AEC) is being prepped for its first field demonstration pilots and commercial trials. The technology, which works by using electrolysis to extract PFAS molecules from water and deposit them onto special membranes, boasts better power efficiency, greater specificity for PFAS, extremely high (99.9%+) removal efficiency, and minimal generation of PFAS-laden waste.

Recently our technology was featured in an article by Global Water Intelligence, a leader in market research and technology expertise in the water industry as an “emerging solution” for the PFAS threat. The article, which was in their popular "CTO Roundup Edition", can be found here: https://www.globalwaterintel.com/global-water-intelligence-magazine/22/5/market-map/pfas-treatment-market-concentrates-on-waste-reduction-and-total-destruction 

We are pleased to see our technology being highlighted by recognized thought-leaders in the area of advanced water treatment. As the technology rolls out in its first trials and commercial deployments, articles such as this one will be valuable tools to spread the word about how the BioLargo AEC has the potential to make PFAS treatment more affordable and environmentally friendly everywhere.

Some excerpts from the article include:

“Technology company BioLargo has developed a system that purportedly helps reduce the residuals issue. Its technology exploits the polarity of PFAS molecules, by separating two chambers with a membrane. Each chamber contains an oppositely charged electrode, which pulls the PFAS onto the membrane, where it stays bound. The key benefit to BioLargo’s technology, which is entering the commercial trialling stage, is how little wasted membrane is produced – the company claims it can treat 1 million gallons of water to 70ppt of PFAS with only 12g of membrane material. This produces far less waste for utilities or industrial users to deal with.”

“While sample processing can be expedited by paying a premium for two- to three-day turnaround, laboratories in the US are inundated and there remains a gap in the market for methods of delivering rapid results. “The technology for monitoring PFAS has not developed as fast as the regulations are developing,” observed Tonya Chandler, director of strategic marketing and business development at BioLargo.”

 

Wednesday, 19 May 2021

BioLargo CEO says 'hard work is paying off' with balance sheet improvement in its 1Q financials

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive the developer of sustainable cleantech technologies that its balance sheet is improving according to its latest financial report.

Calvert says what's more, the California-based company is working with prospective partners to plan and schedule as soon as possible the first commercial pilots for its AEC technology -- which is at the heart of BioLargo’s platform to remove toxic polyfluoroalkyl substances (PFAS) from water.